SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates1/15/2007 9:57:43 AM
  Read Replies (1) of 1022
 
4- Antibody AG Closes CHF 17 Million Series A Financing, Bringing the Total Series A Financing to CHF 23 Million ($ 18.5Million)
Monday January 15, 5:14 am ET

BASEL, Switzerland, January 15 /PRNewswire/ -- Advent Venture Partners, Life Science Partners (LSP) and BioMedinvest today announced the completion of a CHF 17 Million Series A financing of 4-Antibody AG. This closing was led by new investor Advent Venture Partners (UK), together with existing lead investors Life Sciences Partners (LSP, The Netherlands) and BioMedinvest AG (Switzerland). All other existing investors; Grazia Equity (Germany), Mulligan Biocapital (Germany) and several private investors also participated

4-Antibody AG is focused on exploiting its 4mAb(TM) proprietary platform to improve existing antibodies and to discover de- novo fully human antibodies. Proceeds will be used to accelerate the discovery and development of novel therapeutic monoclonal antibodies.

"The success of our Series A financing is a recognition of the potential of our proprietary 4mAb(TM) platform to generate novel fully human antibodies against a broad range of disease targets. We are very pleased to be able to attract Advent Venture Partners, a top tier Life Sciences investor, complementing our existing investor syndicate. We are now well positioned to build on our product pipeline and to accelerate our fast follower monoclonal antibody programs" said Sijmen de Vries, CEO of 4-Antibody AG.

Raj Parekh, General Partner at Advent Venture Partners commented:

"The 4mAb(TM) technology has the potential to become an industry standard to increase the potency and specificity of human monoclonal antibodies designed for therapeutic use. We are very pleased to support the company."

About 4-Antibody AG

4-Antibody AG is a Basel-based privately owned company, with a wholly owned subsidiary in Jena, Germany. 4-Antibody owns a novel and proprietary technology platform (4mAb(TM)) for the development and/or optimization of fully human antibodies. For more information about 4-Antibody, please visit our website at 4-antibody.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext